Dr. Popat on the DREAMM-1 Trial in Relapsed/Refractory Multiple Myeloma

November 28, 2019
Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD

Special Issues, Emerging MOAs in Multiple Myeloma: Updates From the 17th IMW, Volume 1, Issue 1

Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, discusses results from the phase I, dose-expansion DREAMM-1 trial in relapsed/refractory multiple myeloma.

Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, consultant hematologist, University College Hospital, honorary clinical senior lecturer, University College London Cancer Institute, North Thames Clinical Research Network Specialty Lead for Hematology, Cancer Division, discusses results from the phase I, dose-expansion DREAMM-1 trial in relapsed/refractory multiple myeloma.

DREAMM-1 investigated the BCMA antibody-drug conjugate GSK2857916 for the first time in humans, explains Popat. Patients enrolled had progressive multiple myeloma after autologous stem cell transplant, or treatment with alkylators, proteasome inhibitors, and immunomodulatory agents.

In part 2 of the trial, heavily pretreated patients who were refractory to both an immunomodulatory agent and proteasome inhibitor had a nearly 60% overall response rate and median progression-free survival of 7.9 months was noted with the 3.4 mg/kg recommended dose of GSK2857916, which was identified in part 1 of the trial.

Thrombocytopenia and corneal adverse events including blurred vision, dry eye, and photophobia were commonly reported; however, the treatment was generally well-tolerated, concludes Popat.